Table 2.

Characteristics of MSI-high tumors by BRAF mutation status

BRAF WT (n = 106)BRAF V600E (n = 41)OR (95% CI)
Age (y)68.0 (SD = 12.1)77.7 (SD = 9.2)P < 0.0001
Female53 (65.4)28 (34.6)2.15 (1.01-4.61)
Male53 (80.3)13 (19.7)1.00
Ashkenazi Jewish70 (66.7)35 (33.3)3.00 (1.15-7.79)
Non-Ashkenazi Jewish36 (85.7)6 (14.2)1.00
Ever smoked51 (76.1)16 (23.9)0.71 (0.33-1.50)
Never smoked52 (69.3)23 (30.7)1.00
Pack-years38.8 (SD = 26.3)36.1 (SD = 26.1)P = 0.75
HRT use2 (66.6)1 (33.3)0.74 (0.06-8.63)
No HRT use34 (59.7)23 (40.4)1.00
Aspirin/NSAID use25 (69.4)11 (30.6)1.24 (0.54-2.85)
No aspirin/NSAID Use79 (73.8)28 (26.2)1.00
First-degree family history of CRC9 (69.2)4 (30.8)1.15 (0.33-3.97)
No family history of CRC96 (72.2)37 (27.8)1.00
MSI-high106 (72.1)41 (27.9)